Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies
SP Treon, L Xu, ML Guerrera, C Jimenez… - Journal of Clinical …, 2020 - ascopubs.org
Next-generation sequencing has revealed recurring somatic mutations in Waldenström
macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A …
macroglobulinemia (WM), including MYD88 (95%-97%), CXCR4 (30%-40%), ARID1A …
Circulating tumor DNA in lymphoma: principles and future directions
Lymphomas are heterogeneous tumors with striking genetic diversity and variable outcomes
even within pathologic diagnoses. Treatment response assessment relies on radiologic and …
even within pathologic diagnoses. Treatment response assessment relies on radiologic and …
Diagnosis and management of Waldenström macroglobulinaemia—A British Society for Haematology guideline
G Pratt, D El‐Sharkawi, J Kothari, S D'Sa… - British journal of …, 2022 - Wiley Online Library
Scope The objective of this guideline is to provide healthcare professionals with clear
guidance on the management of patients with Waldenström macroglobulinaemia. In …
guidance on the management of patients with Waldenström macroglobulinaemia. In …
Digital droplet PCR in hematologic malignancies: a new useful molecular tool
S Galimberti, S Balducci, F Guerrini, M Del Re… - Diagnostics, 2022 - mdpi.com
Digital droplet PCR (ddPCR) is a recent version of quantitative PCR (QT-PCR), useful for
measuring gene expression, doing clonality assays and detecting hot spot mutations. In …
measuring gene expression, doing clonality assays and detecting hot spot mutations. In …
[HTML][HTML] MYD88 in the driver's seat of B-cell lymphomagenesis: From molecular mechanisms to clinical implications
RAL de Groen, AMR Schrader, MJ Kersten… - …, 2019 - ncbi.nlm.nih.gov
More than 50 subtypes of B-cell non-Hodgkin lymphoma (B-NHL) are recognized in the most
recent World Health Organization classification of 2016. The current treatment paradigm …
recent World Health Organization classification of 2016. The current treatment paradigm …
Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma
Normal cell counterparts of solid and myeloid tumors accumulate mutations years before
disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain …
disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain …
Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia
The diagnosis of Waldenström's macroglobulinemia (WM), an IgM-associated
lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease …
lymphoplasmacytic lymphoma, can be challenging due to the different forms of disease …
Digital PCR: a reliable tool for analyzing and monitoring hematologic malignancies
N Coccaro, G Tota, L Anelli, A Zagaria… - International journal of …, 2020 - mdpi.com
The digital polymerase chain reaction (dPCR) is considered to be the third-generation
polymerase chain reaction (PCR), as it yields direct, absolute and precise measures of …
polymerase chain reaction (PCR), as it yields direct, absolute and precise measures of …
Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic …
Background and Objectives Neuropathy with antibodies to myelin-associated glycoprotein
(MAG) is the most common paraproteinemic IgM neuropathy. Recently, the mutational profile …
(MAG) is the most common paraproteinemic IgM neuropathy. Recently, the mutational profile …
MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies
M Alcoceba, M García-Álvarez, A Medina… - International Journal of …, 2022 - mdpi.com
The MYD88 gene has a physiological role in the innate immune system. Somatic mutations
in MYD88, including the most common L265P, have been associated with the development …
in MYD88, including the most common L265P, have been associated with the development …